Werewolf Therapeutics, Inc.

HOWL Healthcare Biotechnology

Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.

0.98 0.02 −2.00%
Market cap
$48.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
3/9
Altman Z
−4.83
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash and Short Term Investments
57.05 111.00 134.34 129.32 157.53 92.57 17.90
Receivables
— — 1.35 6.93 — — —
Total current assets
58.59 113.07 138.37 140.20 161.07 92.91 18.06
Property, Plant, Equpment (Net)
4.69 6.32 7.96 8.99 2.91 0.65 0.24
Long-term assets (Other)
0.91 1.54 21.62 2.59 1.86 0.21 0.21
Total non-current assets
10.81 13.86 36.46 20.05 18.18 3.48 3.62
Total Assets
69.40 126.93 174.83 160.25 179.25 96.40 21.68
Notes Payable
28.24 — 6.67 — — — —
Accounts Payable
0.75 3.04 1.34 1.22 2.04 1.02 0.63
Accrued Expenses
5.41 10.59 8.86 14.15 8.77 3.59 0.82
Current Revenue (Deferred)
— — 0.91 6.53 — — —
Total current liabilities
36.15 15.18 19.38 23.99 11.87 5.28 2.04
Long Term Debt (Total)
— 26.10 32.66 12.60 14.59 1.86 9.84
Non-current Revenue (Deferred)
— — 0.43 1.13 — — —
Liabilities (Preferred Stock)
— — — — — 141.08 41.37
Non-current Liabilities (Other)
0.76 2.83 — 0.19 — 0.03 0.02
Total non-current liabilities
8.44 38.36 44.08 13.92 14.59 142.98 43.94
Total liabilities
44.59 53.54 63.46 37.91 26.46 148.26 45.98
Additional Paid In Capital
500.21 487.97 455.44 429.04 405.68 0.00 0.10
Common Stock (Net)
0.01 0.01 0.00 0.00 0.00 0.00 0.00
Retained Earnings
(475.41) (414.59) (344.07) (306.70) (252.89) (51.86) (24.41)
Common Equity (Total)
24.81 73.39 111.37 122.34 152.79 (51.86) (24.30)
Shareholders Equity (Total)
24.81 73.39 111.37 122.34 152.79 (51.86) (24.30)
Shareholders Equity and Liabilities (Total)
69.40 126.93 174.83 160.25 179.25 96.40 21.68
Shares (Common)
48.60 44.83 39.11 31.43 27.31 1.18 27.54
Shareholders Equity (Tangible)
24.81 73.39 111.37 122.34 152.79 (51.86) (24.30)
Net Debt
(57.05) (84.90) (101.69) (116.71) (142.94) (90.71) (8.05)
Total Debt
— 26.10 32.66 12.60 14.59 1.86 9.84

Fold the line items

In millions of $ except per-share values · columns are period end dates